A new drug from Schering-Plough Corp aimed at helping patients emerge more quickly from anaesthesia has been recommended for approval in Europe, the region’s medicines watchdog said on Monday.
The European Medicines Agency said Bridion, also known generically as sugammadex, was recommended for the reversal of neuromuscular block induced by rocuronium or vecuronium.
Recommendations for marketing approval by the agency’s Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
Schering-Plough acquired the drug after buying Organon BioSciences, the drugs arm of Akzo Nobel, last year.
A U.S. Food and Drug Administration expert panel voted in March that the drug was safe and effective.
Reviewed by Ramaz Mitaishvili, MD
